Business Wire

Biomax Informatics software licensed by global pharma company, Boehringer Ingelheim, to build a target discovery knowledge platform

Del

Biomax Informatics AG announces that their longtime client, Boehringer Ingelheim, has signed a multi-year license for the BioXM™ Knowledge Management Environment to support their global target discovery research. In addition, the company has extended their license for Biomax’s BioRS™ Integration and Retrieval System.

Boehringer Ingelheim is using the BioXM™ Knowledge Management Environment to build and maintain a target discovery knowledge platform that supports the company’s research on a global scale. The BioXM platform leverages Boehringer Ingelheim’s existing BioRS infrastructure to semantically integrate information from the company’s in-house systems and other proprietary and public data sources including pathways, compounds, sequences, genotypes, phenotypes, experimental data and text mining results. The BioXM platform allows all of the company’s external applications to access the data either directly or through application programming interfaces (APIs) and automates the updating of all integrated databases on a regular schedule.

“Boehringer Ingelheim has used the BioRS software for data integration for many years. Adding the BioXM software now lets them model their complete target discovery process in one easy-to-use, sustainable knowledge hub,” explained Dr. Kaj Albermann, who manages the Boehringer Ingelheim project at Biomax.

About Boehringer Ingelheim

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 143 affiliates and a total of around 50,000 employees. The focus of the family-owned company, founded in 1885, is researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine. www.boehringer-ingelheim.com

About Biomax

Biomax Informatics provides computational solutions for better decision making and knowledge management in the life sciences. They help customers generate value by integrating information from proprietary and public resources to enable a knowledge-based approach to developing innovative life science products. Biomax’s worldwide customer community includes clinics, companies and research organizations that are successful in drug discovery, diagnostics, fine chemicals, food and plant production. www.biomax.com

Biomax, BioRS and BioXM are registered trademarks of Biomax Informatics AG in Germany and other countries. Registered names, trademarks, etc., used in this document, even when not specifically marked as such, are not to be considered unprotected by law.

Contact information

Biomax Informatics AG
Dr. Philipp Krubasik, +49 89 895574-0
philipp.krubasik@biomax.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Arch Capital Group Ltd. Names Janice Englesbe Senior Vice President, Chief Risk Officer20.2.2019 15:10:00Pressemelding

Arch Capital Group Ltd. (“Arch”) today announced that Janice Englesbe will join the Company as Senior Vice President, Chief Risk Officer (CRO) effective February 25, 2019. Ms. Englesbe will be based in Arch’s Bermuda office and report to François Morin, the Company’s Executive Vice President and Chief Financial Officer. As CRO, Ms. Englesbe will have overall responsibility for the Company’s risk management function. Additionally, she will help formulate and implement business strategies and provide comprehensive counsel to the executive leaders and board members. “Janice brings a wealth of experience and demonstrated ability to implement practical results,” Mr. Morin said. “I’m looking forward to the unique perspective and leadership she will bring to Arch.” Ms. Englesbe has over 25 years of risk and finance experience, including Group Deputy Chief Risk Officer of General Re, and has been named one of Intelligent Insurer’s 100 Influential Women in Re/insurance. She holds a bachelor’s d

Ingram Micro and MassChallenge Name Comet Competition Top B2B Startups20.2.2019 15:00:00Pressemelding

Ingram Micro Inc., in partnership with MassChallenge, today announced the top 12 finalists from its Tel Aviv, Austin, and Boston Comet Competition s. The finalists for this year’s inaugural competition are Verifyoo, Perimeter 81, ITsMine, EyeControl, ClearBlade, re:3D, Sempulse, The Mentor Method, Pixm Inc., addapptation, OnRout, and BOXOLOGIC.COM. Established in 2018, the Comet Competition is the only startup challenge dedicated to discovering talented B2B independent software vendors (ISVs) and accelerating their trajectory to channel market success. As Comet Competition finalists, these startups will receive go-to-market funding, unparalleled access to top corporate partners, and tailored curriculum to accelerate their success – all for zero equity. “In order to continue to be a leader in the digital economy, we need to actively search for the world’s best technology startups and catapult their trajectory to profitability and scale,” says Nimesh Davé, executive vice president, Ingra

KCI Launches ABTHERA™ Therapy in Japan20.2.2019 14:30:00Pressemelding

KCI, an Acelity Company, today announced the launch of ABTHERA™ Open Abdomen Negative Pressure Therapy in Japan, expanding access to the Company’s surgical portfolio in the country. ABTHERA™ Therapy is a temporary abdominal closure system that allows surgeons to take control in managing challenging abdominal wall openings where primary closure is not possible and/or repeat abdominal entries are necessary. “When dealing with patients managed with damage control for severe abdominal hemorrhage, abdominal compartment syndrome or severe peritonitis, using ABTHERA™ Therapy has been shown to be associated with proven patient outcomes,” said Dr. Demetrios Demetriades, Professor of Surgery, Keck USC School of Medicine and the Director of the USC Division of Trauma, Emergency Surgery and Surgical Intensive Care Unit. “With the introduction of ABTHERA™ Therapy in Japan, clinicians now have a clinically demonstrated solution for a previously unmet, significant need, that manages the open abdomen

ResMed and Fisher & Paykel Healthcare Announce Settlement of Global Patent Infringement Litigation20.2.2019 14:00:00Pressemelding

ResMed (NYSE: RMD, ASX: RMD), and Fisher & Paykel Healthcare (NZX: FPH, ASX: FPH) today announced an agreement to settle all outstanding patent infringement disputes between the companies in all venues around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190220005556/en/ The settlement involves no payment or admission of liability by either side. Under the agreement, all ongoing infringement proceedings against named products will be dismissed, and each party will bear its own attorney fees and costs incurred in the global proceedings. All other terms remain confidential. As a result of the settlement, there will be no further infringement proceedings against ResMed products, including AirSense flow generators, AirFit P10, Swift LT and Swift FX masks, and ClimateLine heated tubes; or against Fisher & Paykel Healthcare products including Simplus, Eson and Eson 2. “I am pleased we were able to resolve these dispute

IDEMIA Changes Its Management Structure to Consolidate Its Augmented Identity Global Leadership and Appoints Pierre Barrial CEO of Its New Secure Enterprise Transactions Division20.2.2019 13:28:00Pressemelding

IDEMIA today announced the appointment of Pierre Barrial as CEO of the newly created Secure Enterprise Transactions (SET) division. IDEMIA Group CEO Yann Delabrière today announced that all existing Group transactions business units, i.e. Financial Institutions, Mobile Operators and Connected Objects will be brought together under one division. In addition, the IDEMIA Group is also considering the creation of a new Digital business unit within the SET division. The new division will be led by Pierre Barrial, who previously managed IDEMIA’s Financial Institutions business unit. IDEMIA’s customers, i.e. banks, fintech firms, telecoms operators, smartphone manufacturers, IoT firms and automotive manufacturers, are rising to the challenge of managing online services and getting digital. Against such a backdrop, while IDEMIA will continue to develop its long-time expertise in cutting-edge technologies such as cryptography, artificial intelligence, biometrics or cloud communications, the new

The Peninsula Hotels Named First and Only Hotel Brand to Achieve Forbes Travel Guide Five-Star Status across Entire Portfolio20.2.2019 13:00:00Pressemelding

An Unprecedented Achievement This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190220005389/en/ The Peninsula Hotels named the first and only hotel brand to achieve Forbes Five-Star status for all of its hotels (Photo: Business Wire) Forbes Travel Guide (FTG) today unveiled its annual Star Rating list, which revealed that The Peninsula Hotels had achieved Five-Star status across all ten of its properties. The announcement results in The Peninsula Hotels being the first and only hotel brand to achieve the highest possible FTG rating for all its hotels. Speaking of the achievement, Peter Borer, Chief Operating Officer of The Hongkong and Shanghai Hotels, Limited, owner and operator of The Peninsula Hotels, said: “This exceptional result is the culmination of an immense amount of hard work from colleagues across our ten hotels. Our employees dedicate themselves to providing our guests with the best possible standards of luxury ser